Table 1 Patients characteristics
N = 64 | ||||
|---|---|---|---|---|
Age | years | |||
Mean (SD) | 75.4 | 6.5 | ||
Median | 76 | |||
Range | 58–90 | |||
ECOG performance-status | No. (%) | |||
0 | 63 | 98.4 | ||
1 | 1 | 1.6 | ||
TNM classification (cT) | No. (%) | T1a | 1 | 1.6 |
T1c | 7 | 10.9 | ||
T2a | 10 | 15.6 | ||
T2b | 5 | 7.8 | ||
T2c | 9 | 14.1 | ||
T3a | 19 | 29.7 | ||
T3b | 9 | 14.1 | ||
T4 | 2 | 3.1 | ||
TX | 2 | 3.1 | ||
TNM classification (cN) | No. (%) | N0 | 60 | 93.8 |
N1 | 3 | 4.7 | ||
NX | 1 | 1.6 | ||
Gleason score | No. (%) | ≤ 6 | 8 | 12.5 |
7 | 18 | 28.1 | ||
8 ≤ | 38 | 59.4 | ||
Serum testosterone | ng/dL | |||
Mean (SD) | 11.85 | 11.37 | ||
Median | 10 | |||
Range | 0.03–47 | |||
Serum PSA | ng/mL | |||
Mean (SD) | 6.7 | 7.66 | ||
Median | 3.95 | |||
Range | 1.03–35.13 | |||
History of radical prostatectomy | 29 | 45.3 | ||
With endocrine therapy | 14 | 48.3 | ||
TNM classification (pT) | T1c | 1 | 3.4 | |
T2a | 3 | 10.3 | ||
T2b | 4 | 13.8 | ||
T2c | 3 | 10.3 | ||
T3a | 6 | 20.7 | ||
T3b | 8 | 27.6 | ||
T4 | 2 | 6.9 | ||
TX | 2 | 6.9 | ||
TNM classification (pN) | N0 | 24 | 82.8 | |
N1 | 3 | 10.3 | ||
NX | 2 | 6.9 | ||
Gleason score | ≤ 6 | 1 | 3.4 | |
7 | 8 | 27.6 | ||
8 ≤ | 19 | 65.5 | ||
Missing | 1 | 3.4 | ||
History of radiation therapy | Yes | 48 | 75.0 | |
EBRT | 43 | 89.6 | ||
Brachytherapy | 4 | 8.3 | ||
EBRT + Brachytherapy | 1 | 2.1 | ||
with endocrine therapy | 27 | 56.3 | ||
History of bilateral orchiectomy | 1 | 1.6 | ||
History of GnRH analogue use | 63 | 98.4 | ||
History of bicalutamide use | 64 | 100 | ||
Median administration period | day | 715 | ||
AWS | yes | 46 | 71.9 | |
History of flutamide use | 23 | 35.9 | ||
Median administration period | day | 330 | ||
AWS | yes | 16 | 25.0 |